Mga Batayang Estadistika
| LEI | 549300QCJ6RBUJKI7S66 |
| CIK | 1412486 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cocrystal Pharma, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA, INC |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission |
|
| August 14, 2025 |
Exhibit 99.1 Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs ● Favorable CDI-988 Phase 1 safety and tolerability reported ● Challenge study with CDI-988 as a norovirus preventive and treatment planned later this year BOTHELL, Wash. (August 14, 2025) – Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) |
|
| August 5, 2025 |
Exhibit 99.1 Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference ● All CDI-988 doses, ranging from 100 mg to 1200 mg, in the Phase 1 study were well tolerated ● Company expects to initiate Phase 1b study with CDI-988 in norovirus-infected healthy subjects later this year ● Lack of approved norovirus treatments or vaccines creates cr |
|
| August 5, 2025 |
Presentation dated August 5, 2025 Exhibit 99.2 |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission F |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2025 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| July 10, 2025 |
Exhibit 99.1 Cocrystal Pharma to Presents Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference BOTHELL, Wash. (July 10, 2025) – Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for an oral presentation at the 9th International Calicivirus Conferenc |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| June 18, 2025 |
Amendment No. 1 to Amended and Restated Bylaws Exhibit 3.1 Cocrystal Pharma Inc. Amendment No. 1 to Amended and Restated Bylaws Section 7 of the Amended and Restated Bylaws is hereby amended to read in its entirety as follows: Section 7. Stockholder Quorum and Voting. One third of the aggregate voting power of the outstanding shares of all classes or series of voting stock then entitled to vote, represented in person or by proxy, shall constit |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| June 5, 2025 |
Exhibit 99.1 Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference BOTHELL, Wash. (JUNE 5, 2025) – Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the 2025 Military Health System Research Symposium (MHSRS) being held August 4-7 in Kissimmee, Fla. Cocryst |
|
| May 29, 2025 |
Exhibit 99.1 Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain ● CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain ● The Company’s virology study further confirmed the previous structural and in vitro data that revealed the binding |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| May 15, 2025 |
Exhibit 99.1 Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, Wash. (May 15, 2025) – Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three m |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA, IN |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by Registrant ☒ Filed by Party other than Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Prox |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by Registrant ☒ Filed by Party other than Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Prox |
|
| April 24, 2025 |
Exhibit 99.1 Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants ○ Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025 ○ Cocrystal Pharma’s pan-viral protease inhibitor CDI-988 shows superior broad-spectrum antiv |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of in |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of in |
|
| April 23, 2025 |
Cocrystal Pharma, Inc. Corporate Presentation, dated April 23, 2025 Exhibit 99.1 |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| April 8, 2025 |
Exhibit 10.1 COCRYSTAL PHARMA, INC. 2025 EQUITY INCENTIVE PLAN Adopted: April 2, 2025 1. DEFINITIONS The following terms shall have the following meanings unless the context indicates otherwise: 1.1. “Affiliate” and “Associate” shall have the respective meanings given to such terms under Rule 12b-2 under the Exchange Act. 1.2. “Award” shall mean either a Stock Option, an SAR, a Stock Award, an RSU |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission F |
|
| March 31, 2025 |
Exhibit 99.1 Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs BOTHELL, Wash. (March 31, 2025) – Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the 12 months ended December 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. “O |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38418 Cocrystal Pharma, Inc. (Exact name of registrant as specif |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission F |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of |
|
| January 13, 2025 |
Cocrystal Pharma, Inc. Corporate Presentation, dated January 13, 2025 Exhibit 99.1 |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of i |
|
| January 8, 2025 |
Exhibit 99.1 Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections ● Data show favorable safety and tolerability with dosing up to 800 mg for 10 days ● Plans to initiate human challenge study in 2025 in norovirus-infected subjects BOTHELL, Wash. (January 8, 2025) – Cocrystal Pharm |
|
| December 31, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of |
|
| December 31, 2024 |
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 Exhibit 99.1 Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 ● Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuations ● Enrollment to be extended due to low influenza infection among challenged participants; virology results are uninterpretable BOTHELL, Wash. (December 31, 20 |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA |
|
| November 13, 2024 |
Certificate of Incorporation, as amended Exhibit 3.1 CERTIFICATE OF INCORPORATION OF COCRYSTAL PHARMA, INC. (Conformed copy incorporating all amendments through November 13, 2024) 1. The name of the corporation is Cocrystal Pharma, Inc. (the “Company”). 2. The address of its registered office in the State of Delaware, County of New Castle, is 3411 Silverside Road, Rodney Building #104, Wilmington, Delaware 19810. The name of its register |
|
| November 13, 2024 |
Exhibit 99.1 Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs BOTHELL, Wash. (November 13, 2024) – Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and nine months ended September 30, 2024, and provides updates on its antiviral product pipeline, upcoming mileston |
|
| November 13, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commissio |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of |
|
| October 31, 2024 |
Exhibit 99.1 Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins The Company’s antiviral candidate for seasonal and pandemic influenza shows in vitro activity against the avian influenza A PB2 protein, whereas current influenza vaccines offer no protection against pandemic avian influenza BO |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2024 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of i |
|
| August 20, 2024 |
Exhibit 99.1 Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences BOTHELL, Wash. (August 19, 2024) – Cocrystal Pharma, Inc.’s (Nasdaq: COCP) management announces its participation in the upcoming Virtual Investor Summit Microcap Forum in August and the H.C. Wainwright 26th Annual Global Investment Conference in September. “We look |
|
| August 20, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of i |
|
| August 14, 2024 |
Exhibit 99.1 Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs ● Expects to report topline results in 2025 from Phase 2a influenza A human challenge study with oral CC-42344, including initial indication of virology ● In vitro testing shows CC-42344 inhibits the avian influenza A (H5N1) PB2 protein recently identified in |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA, INC |
|
| July 18, 2024 |
Exhibit 99.1 Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor BOTHELL, Wash. (July 18, 2024) – Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 |
|
| July 18, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of inc |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 28, 2024 |
Certificate of Amendment to Certificate of Incorporation – reduce number of authorized shares Exhibit 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF COCRYSTAL PHARMA, INC. Cocrystal Pharma, Inc. (the “Company”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”), hereby certifies as follows: 1. The name of the Company is Cocrystal Pharma, Inc. 2. Pursuant to Section 242 of the Delaware Ge |
|
| June 20, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of inc |
|
| June 20, 2024 |
Exhibit 99.1 New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows BOTHELL, Wash. (June 20, 2024) – Cocrystal Pharma, Inc.’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein r |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA, IN |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| May 13, 2024 |
Exhibit 99.1 Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs ● Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 ● Enrollment completed in Phase 2a influenza A human challenge study of oral CC-42344 |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by Registrant ☒ Filed by Party other than Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Prox |
|
| May 1, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| May 1, 2024 |
Exhibit 99.1 Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza BOTHELL, Wash. (May 1, 2024) – Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human chal |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by Registrant ☒ Filed by Party other than Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Prox |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38418 Cocrystal Pharma, Inc. (Exact name of |
|
| March 28, 2024 |
Exhibit 97 COCRYSTAL PHARMA, INC. CLAWBACK POLICY Introduction Cocrystal Pharma, Inc. (the “Company”) adopts this Clawback Policy in accordance with the recently adopted SEC Rule and the Nasdaq Stock Market’s implementation of the Rule. Senior management has acted prior to the next regularly scheduled meeting of the Board of Directors (the “Board”) in reliance upon the advice of counsel that techn |
|
| March 28, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission F |
|
| March 28, 2024 |
Exhibit 19.1 MEMORANDUM TO: All Officer, directors, Employees and Certain Third Parties FROM: Nason, Yeager, Gerson, Harris & Fumero, P.A. DATE: March 23, 2024 RE: Insider Trading Policy We believe that the best way to protect Cocrystal Pharma, Inc. (the “Company”) and its executive officers, directors and employees from potential liability from the insider trading under the federal securities law |
|
| March 28, 2024 |
Exhibit 99.1 Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs ● FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum PB2 inhibitor ● Topline data expected in 2024 from Phase 2a influenza A hu |
|
| March 28, 2024 |
Exhibit 14.1 Code of Ethics As Approved March 23, 2024 1 Introduction The reputation of Cocrystal Pharma, Inc. (the “Company”) is built upon basic principles of ethical behavior, individual integrity and personal commitment. This reputation can be retained only if all the Company’s employees establish and adhere to the highest moral and ethical standards in the conduct of the Company’s business. T |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38418 Cocrystal Pharma, Inc. (Exact name of registrant as specif |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of in |
|
| March 19, 2024 |
Exhibit 99.1 Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash. (March 19, 2024) – Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received Pre-Investigational New Drug (Pre-IND) feedback from the U.S. Food and |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of i |
|
| January 8, 2024 |
Cocrystal Pharma, Inc. Corporate Presentation, dated January 8, 2024 Exhibit 99.1 |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of i |
|
| January 4, 2024 |
Exhibit 99.1 Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates BOTHELL, Wash. (January 4, 2024) – Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides an update on the clinical development of its oral first-in-class pan-norovirus and pan-coronavirus dual protease inhibitor CDI-988 and its oral |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of |
|
| December 6, 2023 |
Exhibit 99.1 Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A BOTHELL, Wash. (December 6, 2023) – Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the achievement of first-patient-in for the Phase 2a human challenge clinical trial with CC-42344, an investigational new oral anti |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of |
|
| December 4, 2023 |
Cocrystal Pharma, Inc. Corporate Presentation, dated December 4, 2023 Exhibit 99.1 |
|
| December 4, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction of incorporation) (Commission |
|
| November 29, 2023 |
Exhibit 99.2 Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast BOTHELL, Wash. (November 29, 2023) – Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces the presentation of favorable data demonstrating activity of its potent broad-spectrum PB2 inhibitor CC-42344 against pandemic and seasonal inf |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction of incorporation) (Commissio |
|
| November 29, 2023 |
Cocrystal Pharma, Inc. Corporate Presentation, dated November 28, 2023 Exhibit 99.1 |
|
| November 13, 2023 |
Exhibit 99.1 Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs ● Enrollment underway in Phase 1 trial with novel protease inhibitor CDI-988, the first potential dual coronavirus-norovirus oral antiviral ● Dosing expected to begin later this year in Phase 2a human challenge trial with oral CC-42344 for the treatment of pand |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commissio |
|
| October 31, 2023 |
Exhibit 99.1 Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 BOTHELL, Wash. (October 31, 2023) – Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces receipt of authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 2a human c |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other jurisdiction (Commission (IRS Employer of |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission |
|
| August 16, 2023 |
Exhibit 99.1 August 14, 2023 Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs ● On track to begin a Phase 2a trial in the second half of 2023 with CC-42344 for the treatment of pandemic and seasonal influenza A ● Selected the novel protease inhibitor CDI-988 as development lead in the oral norovirus program ● CDI-988, th |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA, INC |
|
| June 15, 2023 |
H.C. Wainwright & Co. The date of this prospectus supplement is June 15, 2023 Filed pursuant to Rule 424(b)(5) Registration No. 333-271883 PROSPECTUS SUPPLEMENT (To the Prospectus dated May 24, 2023) Up to $7,250,000 of Common Stock We have entered into an At-The-Market Offering Agreement (the “Offering Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (the “Agent” or “Wainwright”), relating to shares of our Common Stock, par value $0.001 per share (the “Common St |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| May 24, 2023 |
Cocrystal Pharma, Inc. 19805 North Creek Parkway Bothell, Washington 98011 May 24, 2023 Cocrystal Pharma, Inc. 19805 North Creek Parkway Bothell, Washington 98011 May 24, 2023 Via EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D. C. 20549 Attention: Ms. Lauren Hamill Re: Cocrystal Pharma, Inc. Registration Statement on Form S-3 File No. 333-271883 Dear Ms. Hamill: In accordance with Rule 461 promulgated pursuant to the Securiti |
|
| May 24, 2023 |
As filed with the Securities and Exchange Commission on May 24, 2023 As filed with the Securities and Exchange Commission on May 24, 2023 Registration No. |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA, IN |
|
| May 15, 2023 |
Exhibit 99.1 Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs BOTHELL, Wash. (May 15, 2023) – Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the three months ended March 31, 2023 and provides updates on its antiviral pipeline, upcoming milestones and business activities. “Re |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| May 12, 2023 |
As filed with the Securities and Exchange Commission on May 12, 2023 As filed with the Securities and Exchange Commission on May 12, 2023 Registration No. |
|
| May 12, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Cocrystal Pharma, Inc. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by Registrant ☒ Filed by Party other than Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Prox |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission F |
|
| April 24, 2023 |
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors Exhibit 99.1 Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors BOTHELL, Wash. (April 24, 2023) – Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the appointment of Fred Hassan to its Board of Directors, increasing its Board membership to six. Mr. Hassan’s distinguished 40-year career includes serving in senior executive and director |
|
| April 14, 2023 |
US19188J4094 / COCRYSTAL PHARMA INC / FROST PHILLIP MD ET AL Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Cocrystal Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19188J409 (CUSIP Number) Phillip Frost, M.D. Frost Gamma Investments Trust 4400 Biscayne Boulevard Miami, Florida 33137 (305) 575-6015 (Name |
|
| April 12, 2023 |
US19188J4094 / COCRYSTAL PHARMA INC / Hassan Fred Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Cocrystal Pharma, Inc. (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Securities) 19188J409 (CUSIP Number) April 4, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2023 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| April 10, 2023 |
Securities Purchase Agreement dated April 1, 2023 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) entered into as of this 4th day of April, 2023 (the “Effective Date”) by and between the parties on the signature page to this Agreement (each, a “Purchaser”), and Cocrystal Pharma, Inc., a Delaware corporation (“COCP”) (collectively, the Purchasers and COCP are the “Parties”). WHEREAS, this Agreement c |
|
| April 10, 2023 |
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules BOTHELL, Wash. (April 10, 2023) – Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the completion of a private placement of 2,030,458 shares of common stock at a price of $1.97 per share for proceeds of $4.0 million. Investors in the private placement were Cocrysta |
|
| April 4, 2023 |
Opinion of the United States Court of Appeals for the Third Circuit Exhibit 99.1 |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission F |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38418 Cocrystal Pharma, Inc. (Exact name of registrant as specif |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission F |
|
| March 15, 2023 |
Transcript of Interview with Dr. Sam Lee, Co-Chief Executive Officer of Cocrystal Pharma, Inc. Exhibit 99.1 |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission |
|
| January 9, 2023 |
Cocrystal Pharma, Inc. Corporate Presentation, dated January 9, 2023 EX-99.1 2 ex99-1.htm Exhibit 99.1 |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA |
|
| October 26, 2022 |
Exhibit 99.1 Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 BOTHELL, Wash. (October 26, 2022) – Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the completion of enrollment in a Phase 1 healthy volunteer study to assess the safety, tolerability and pharmacokinetics (PK) of its orally administered, novel, broad-spectrum antiviral candidat |
|
| October 26, 2022 |
Cocrystal Pharma, Inc. Corporate Presentation, dated October 26, 2022 Exhibit 99.2 |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2022 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission |
|
| October 3, 2022 |
Certificate of Amendment to Certificate of Incorporation Exhibit 3.1 |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commissi |
|
| September 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commissi |
|
| September 12, 2022 |
Cocrystal Pharma, Inc. Corporate Presentation, dated September 12, 2022 Exhibit 99.1 |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA, INC |
|
| August 15, 2022 |
Exhibit 99.1 Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs ? Planned Phase 2a study design with orally administered CC-42344 for the treatment of pandemic and seasonal influenza A ? Reported pharmacokinetic (PK) data from the single ascending dose portion of its Phase 1 study with CC-42344 supporting once-daily dosing ? Co |
|
| August 15, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2022 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| May 20, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| May 19, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| May 11, 2022 |
Exhibit 99.1 Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones ? Reported favorable preliminary data from the two initial cohorts in its Phase 1 study with CC-42344 for the treatment of pandemic and seasonal influenza A ? Announced a collaboration with the National Institute of Allergy and Infectious Diseases (NI |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA, IN |
|
| May 11, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| April 11, 2022 |
DEF 14A 1 formdef14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by Registrant ☒ Filed by Party other than Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by Registrant ? Filed by Party other than Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Prox |
|
| March 23, 2022 |
Exhibit 99.1 Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones ? Commenced enrollment in Phase 1 trial with orally administered, broad-spectrum antiviral agent CC-42344 for the treatment of pandemic and seasonal influenza A ? Advanced COVID-19 programs with the goal of initiating two Phase 1 trials in 2022 with the intranasal/pulmonary anti |
|
| March 23, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission F |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38418 Cocrystal Pharma, Inc. (Exact name of registrant as specif |
|
| December 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2021 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commissio |
|
| December 22, 2021 |
Exhibit 99.1 Cocrystal Pharma?s COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant Antiviral activity now confirmed against SARS-CoV-2 and all variants of concern including Omicron, Delta, Alpha, Beta and Gamma BOTHELL, Wash. (December 22, 2021) ? Cocrystal Pharma, Inc. (Nasdaq: COCP) (?Cocrystal? or the ?Company?) an |
|
| November 19, 2021 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commissio |
|
| November 15, 2021 |
Exhibit 99.1 Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development Programs and Milestones ? Submitted pre-IND briefing package to the FDA for intranasal/pulmonary CDI-45205 for the treatment of COVID-19 and sets goal of initiating IND-enabling study and Phase 1 in 2022 ? Advance oral COVID-19 program with goal of initiating IND-enabling study and Phase 1 i |
|
| November 15, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commissio |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA |
|
| September 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2021 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commissi |
|
| September 14, 2021 |
Cocrystal Pharma, Inc. Corporate Presentation, dated September 2021 Exhibit 99.1 |
|
| August 16, 2021 |
Consulting and Scientific Advisory Board Agreement, dated April 13, 2021 with Roger Kornberg Exhibit 10.1 CONSULTING AND SCIENTIFIC ADVISORY BOARD AGREEMENT This Agreement, dated as of April 13, 2021, is made and entered into by and between Cocrystal Discovery, Inc., a Delaware corporation (the ?Company?) and Roger Kornberg, an individual whose principal residence is in California (?Advisor?). 1. Services 1.1 Scope of Services. During the Term (as defined below), Advisor will serve as a c |
|
| August 16, 2021 |
Certificate of Incorporation, as amended Exhibit 3.1 CERTIFICATE OF INCORPORATION OF COCRYSTAL PHARMA, INC. (Conformed copy incorporating all amendments through August 6, 2021) 1. The name of the corporation is Cocrystal Pharma, Inc. (the ?Company?). 2. The address of its registered office in the State of Delaware, County of New Castle, is 3411 Silverside Road, Rodney Building #104, Wilmington, Delaware 19810. The name of its registered |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA, INC |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2021 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| July 12, 2021 |
Cocrystal Pharma, Inc. Corporate Presentation, dated July 2021 Exhibit 99.1 |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2021 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| June 10, 2021 |
COCP / Cocrystal Pharma Inc / FROST PHILLIP MD ET AL - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Cocrystal Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19188J300 (CUSIP Number) Phillip Frost, M.D. Frost Gamma Investments Trust Steven D. Rubin 4400 Biscayne Boulevard Miami, Florida 33137 (305) 575-6015 (Na |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 28, 2021 |
Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox Exhibit 99.1 Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox BOTHELL, Wash. (May 28, 2021) ? With great sadness, Cocrystal Pharma, Inc. (Nasdaq: COCP), (?Cocrystal? or the ?Company?) announces that Gary Wilcox, Ph.D., Chairman, CEO and co-founder, suddenly passed away Wednesday, May 26 at the age of 74. The Board of Directors and staff of Cocrystal extend the |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 COCRYSTAL PHARMA INC (Name of Issuer) Common Shares (Title of Class of Securities) 19188J300 (CUSIP Number) FiveT Investment Management Ltd c/o DMS Corporate Services, Suite 5B201, 2nd Floor, One Nexus Way Camana Bay, Grand Cayman, Cayman Islands KY1-1108 +1 345 749 2552 ( |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA |
|
| May 5, 2021 |
26,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-237738 PROSPECTUS SUPPLEMENT (To the Prospectus dated May 13, 2020) 26,000,000 Shares of Common Stock We are offering 26,000,000 shares of our common stock, par value $0.001 per share, at a purchase price of $1.54 per share pursuant to this prospectus supplement and the accompanying prospectus. The offering is being underwritten on a firm commi |
|
| May 5, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation |
|
| May 5, 2021 |
Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock Exhibit 99.1 Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock BOTHELL, Wash., May 4, 2021 ? Cocrystal Pharma, Inc. (Nasdaq: COCP), (?Cocrystal? or the ?Company?), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, tod |
|
| May 5, 2021 |
Exhibit 1.1 26,000,000 SHARES of Common Stock Cocrystal Pharma, Inc. UNDERWRITING AGREEMENT May 4, 2021 H.C. Wainwright & Co., LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: The undersigned, Cocrystal Pharma, Inc.,, a company incorporated under the laws of Delawa |
|
| May 5, 2021 |
Other Events, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation |
|
| April 26, 2021 |
Amendment to 2015 Equity Incentive Plan* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by Registrant [X] Filed by Party other than Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Defin |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 16, 2021 |
PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-38418 Cocrystal Pharma, Inc. (Exact name of registrant as sp |
|
| March 9, 2021 |
Cocrystal Pharma, Inc. Corporate Presentation, dated March 2021 Exhibit 99.1 |
|
| March 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2021 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commissio |
|
| February 19, 2021 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF COCRYSTAL PHARMA, INC. Article I. Meeting of Stockholders Section 1. Annual Meeting. The annual meeting of the stockholders of this Company shall be held at the time and place designated by the Board of Directors of the Company. Business transacted at the annual meeting shall include the election of directors of the Company. Section 2. Special Meetings. S |
|
| February 16, 2021 |
CUSIP No: 19188J300 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Cocrystal Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 19188J300 (CUSIP Numbe |
|
| January 21, 2021 |
Exhibit 99.1 . |
|
| January 21, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission |
|
| January 11, 2021 |
Cocrystal Pharma, Inc. Investor Presentation, dated January 2021 Exhibit 99.1 |
|
| January 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission |
|
| December 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commissio |
|
| November 19, 2020 |
COCP / Cocrystal Pharma, Inc. / OPKO HEALTH, INC. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Cocrystal Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19188J300 (CUSIP Number) Camielle Green Associate General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Telephone: (30 |
|
| November 13, 2020 |
10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| November 6, 2020 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 form8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorpora |
|
| October 2, 2020 |
United States District Court DISTRICT OF NEW JERSEY Exhibit 99.1 United States District Court DISTRICT OF NEW JERSEY TRENT NICHOLS and SHARON NICHOLS, derivatively on behalf of COCRYSTAL PHARMA, INC. F/K/A BIOZONE PHARMACEUTICALS, INC., Case No.: 2:19-cv-16751-KM-JBC Plaintiffs, vs. NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTION TO CURRENT COCRYSTAL STOCKHOLDERS ELLIOTT MAZA, GARY WILCOX, JEFFREY MECKLER, GERALD MCGUIRE, JAMES MARTIN, CURTIS DA |
|
| October 2, 2020 |
Other Events, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commissi |
|
| October 2, 2020 |
United States District Court DISTRICT OF NEW JERSEY Exhibit 99.2 United States District Court DISTRICT OF NEW JERSEY TRENT NICHOLS and SHARON NICHOLS, derivatively on behalf of COCRYSTAL PHARMA, INC. F/K/A BIOZONE PHARMACEUTICALS, INC., Plaintiffs, vs. ELLIOTT MAZA, GARY WILCOX, JEFFREY MECKLER, GERALD MCGUIRE, JAMES MARTIN, CURTIS DALE, RAYMOND SCHINAZI, DAVID BLOCK, PHILLIP FROST, JANE H. HSIAO, STEVEN RUBIN, BRIAN KELLER, BARRY C. HONIG, JOHN ST |
|
| August 27, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorpora |
|
| August 27, 2020 |
Exhibit 99.1 Cocrystal Pharma Increases Previously Announced Bought Deal to $15.0 Million BOTHELL, WA, August 26, 2020 – Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that, due to demand, the underwriter has agreed to increase the size of its previously announced |
|
| August 27, 2020 |
Other Events, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission |
|
| August 27, 2020 |
Exhibit 1.1 14,285,715 SHARES of Common Stock Cocrystal Pharma, Inc. AMENDED AND RESTATED UNDERWRITING AGREEMENT August 26, 2020 H.C. Wainwright & Co., LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: The undersigned, Cocrystal Pharma, Inc., a company incorporated |
|
| August 27, 2020 |
Cocrystal Pharma Announces $10.0 Million Bought Deal Offering Exhibit 99.1 Cocrystal Pharma Announces $10.0 Million Bought Deal Offering BOTHELL, WA, August 26, 2020 – Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter |
|
| August 27, 2020 |
Financial Statements and Exhibits, Other Events 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorpora |
|
| August 27, 2020 |
H.C. Wainwright & Co. The date of this prospectus supplement is August 26, 2020 Filed pursuant to Rule 424(b)(5) Registration No. 333-237738 PROSPECTUS SUPPLEMENT (To the Prospectus dated May 13, 2020) 14,285,715 Shares of Common Stock We are offering 14,285,715 shares of our common stock, par value $0.001 per share, at a purchase price of $1.05 per share pursuant to this prospectus supplement and the accompanying prospectus. The offering is being underwritten on a firm commi |
|
| August 26, 2020 |
Subject to Completion dated August 26, 2020 Filed pursuant to Rule 424(b)(5) Registration No. 333-237738 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are |
|
| August 6, 2020 |
Portions of this document have been omitted as permitted by the rules of the Securities and Exchange Commission. |
|
| August 6, 2020 |
10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-384 |
|
| July 2, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| July 2, 2020 |
Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT July 1, 2020 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Cocrystal Pharma, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in this Agreeme |
|
| July 1, 2020 |
H.C. Wainwright & Co. The date of this prospectus supplement is July 1, 2020 Filed pursuant to Rule 424(b)(5) Registration No. 333-237738 PROSPECTUS SUPPLEMENT (To the Prospectus dated May 22, 2020) Up to $10,000,000 of Common Stock We have entered into an At-The-Market Offering Agreement (the “Offering Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (the “Agent” or “Wainwright”), relating to shares of our common stock, par value $0.001 per share (the “Common S |
|
| June 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| June 15, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| June 8, 2020 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| May 13, 2020 |
Portions of this document have been omitted as permitted by the rules of the Securities and Exchange Commission. |
|
| May 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA |
|
| May 12, 2020 |
Cocrystal Pharma, Inc. 9805 North Creek Parkway Bothell, Washington May 12, 2020 Via EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D. C. 20549 Attention: Mr. Tim Buchmiller Re: Cocrystal Pharma, Inc. Registration Statement on Form S-3 File No. 333-237738 Dear Mr. Buchmiller: In accordance with Rule 461 promulgated pursuant to the Securities |
|
| May 11, 2020 |
Cocrystal Pharma, Inc. Corporate Presentation, dated May 2020 Exhibit 99.1 |
|
| May 11, 2020 |
MICHAEL D. HARRIS DIRECT DIAL: (561) 471-3507 ALSO ADMITTED IN NEW YORK E-MAIL ADDRESS: [email protected] May 11, 2020 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission Washington, DC 20549 Attention: Mr. Tim Buchmiller Re: Cocrystal Pharma, Inc. Registration Statement on Form S-3 Filed April 17, 2020 File No. 333-237738 Dear Mr. Buchmiller: Confirming our tel |
|
| May 11, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| May 4, 2020 |
CORRESP 1 filename1.htm Cocrystal Pharma, Inc. 9805 North Creek Parkway Bothell, Washington May 4, 2020 Via EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission Washington, DC 20549 Re: Cocrystal Pharma, Inc. Registration Statement on Form S-3 Filed April 17, 2020 File No. 333-237738 Dear Mr. Buchmiller: Please find our response to the comments received from you in your le |
|
| May 4, 2020 |
As filed with the Securities and Exchange Commission on May 4, 2020 Registration No. |
|
| April 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 28, 2020 |
DEF 14A 1 def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by Registrant [X] Filed by Party other than Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 22, 2020 |
Exhibit 99.1 Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of Action - Expanded license agreement with KSURF further broadens and advances Cocrystal’s COVID-19 program - - Small molecule therapeutic inhibitors against coronaviruses included in agreement have demonstrated strong proof |
|
| April 22, 2020 |
8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporat |
|
| April 20, 2020 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Cocrystal Pharma Announces Appointment of Nobel Laureate and Scientific Advisor, Roger D. Kornberg, Ph.D., to Board of Directors - Work completed over decades of renowned biochemist’s career serves as basis for Company’s structure-based technology which has demonstrated broad utility in development of proprietary antivirals - BOTHELL, WA, April 20, 2020 – Cocrysta |
|
| April 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission F |
|
| April 17, 2020 |
COCP / Cocrystal Pharma, Inc. S-3 - - As filed with the Securities and Exchange Commission on April 17, 2020 Registration No. |
|
| March 30, 2020 |
Exhibit 99.1 Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020 ● Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) ● Continuing collaboration with Merck to discover and develop certain proprietary influenza A/B antiviral agents ● Expecting to |
|
| March 30, 2020 |
Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporat |
|
| March 27, 2020 |
Exhibit 21.1 Subsidiaries of Cocrystal Pharma, Inc. Name of Subsidiary Jurisdiction of Incorporation Cocrystal Discovery, Inc. Delaware Cocrystal Merger Sub, Inc. Delaware |
|
| March 27, 2020 |
COCP / Cocrystal Pharma, Inc. 10-K - Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-38418 Cocrystal Pharma, Inc. (Exact name of registrant as sp |
|
| March 27, 2020 |
Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK The following is a summary of our capital stock and provisions of our amended and restated articles of incorporation and amended and restated by-laws. For more detailed information, please refer to our certificate of incorporation and by-laws, which are filed, or incorporated by reference, as exhibits to the Annual Report on Form 10-K for the year ended Dec |
|
| March 13, 2020 |
Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market Exhibit 99.1 Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market BOTHELL, WA, March 11, 2020 — COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today the closing of its previously announced registered direct offering with seve |
|
| March 13, 2020 |
8-K 1 form8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporatio |
|
| March 13, 2020 |
Form of Securities Purchase Agreement, dated March 9, 2020** Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 9, 2020, and is between Cocrystal Pharma, Inc., a corporation incorporated under the laws of the state of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchaser |
|
| March 10, 2020 |
H.C. Wainwright & Co. The date of this prospectus supplement is March 9, 2020 Filed pursuant to Rule 424(b)(5) Registration No. 333-220632 PROSPECTUS SUPPLEMENT (To the Prospectus dated October 10, 2017) 5,037,038 Shares of Common Stock We are offering up to 5,037,038 shares of our common stock, par value $0.001 per share at a purchase price of $1.35 per share of common stock to certain institutional investors pursuant to this prospectus supplement and the accompanying pros |
|
| March 10, 2020 |
COCP / Cocrystal Pharma, Inc. / Opko Health, Inc. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cocrystal Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19188J300 (CUSIP Number) Kate Inman General Counsel, Secretary OPKO Health, Inc. 4400 Biscayne Boulevard Miami, Florida 33137 Telephone: (305) 575-4100 Ph |
|
| March 9, 2020 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Cocrystal Pharma Announces Plans to Advance Coronavirus Program ● Company has immediately initiated Coronavirus program ● Leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) ● Strong financial position bolsters Company’s ongoing research and development efforts BOTHELL, WA, March 6, 2020 – Cocrystal Pharma, Inc. (N |
|
| March 9, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporati |
|
| March 6, 2020 |
COCP / Cocrystal Pharma, Inc. / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 19188J300 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Cocrystal Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 19188J300 (CUSIP Number |
|
| March 4, 2020 |
Engagement Letter, dated February 26, 2020 Exhibit 10.2 H.C.WAINWRIGHT&CO. February 26, 2020 Cocrystal Pharma, Inc. 19805 N. Creek Parkway Bothell, WA 98011 Attn: Gary Wilcox, Chief Executive Officer Dear Mr. Wilcox: This letter agreement (this “Agreement”) constitutes the agreement between Cocrystal Pharma, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or un |
|
| March 4, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| March 4, 2020 |
Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market Exhibit 99.1 Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market FEBRUARY 28, 2020 BOTHELL, WA, Feb. 28, 2020 (GLOBE NEWSWIRE) — COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today the closing of its previously announced r |
|
| March 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commissio |
|
| March 4, 2020 |
Investor Presentation dated March 2020 Exhibit 99.1 |
|
| March 4, 2020 |
Form of Securities Purchase Agreement, dated February 27, 2020** Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 27, 2020, and is between Cocrystal Pharma, Inc., a corporation incorporated under the laws of the state of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purch |
|
| February 28, 2020 |
H.C. Wainwright & Co. The date of this prospectus supplement is February 27, 2020 Filed pursuant to Rule 424(b)(5) Registration No. 333-220632 PROSPECTUS SUPPLEMENT (To the Prospectus dated October 10, 2017) 8,461,540 Shares of Common Stock We are offering up to 8,461,540 shares of our common stock, par value $0.001 per share at a purchase price of $1.30 per share of common stock to certain institutional investors pursuant to this prospectus supplement and the accompanying pros |
|
| February 28, 2020 |
COCP / Cocrystal Pharma, Inc. / LSP Advisory B.V. - SC 13G/A Passive Investment SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Cocrystal Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 19188J |
|
| February 24, 2020 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commissio |
|
| February 18, 2020 |
Cocrystal Pharma, Inc. Corporate Presentation, dated February 2020 EX-99.1 2 ex99-1.htm |
|
| February 18, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commissio |
|
| February 10, 2020 |
COCP / Cocrystal Pharma, Inc. / LSP Advisory B.V. - SC 13G/A Passive Investment SC 13G/A 1 d881293dsc13ga.htm SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Cocrystal Pharma, Inc. (Name of Issuer) Common Stock (Title |
|
| January 31, 2020 |
The date of this prospectus supplement is January 29, 2020 Filed pursuant to Rule 424(b)(5) Registration No. 333-220632 PROSPECTUS SUPPLEMENT (To the Prospectus dated October 10, 2017) Up to $200,000 maximum aggregate offering price of Common Stock We have entered into an amendment to the amended and restated equity distribution agreement with A.G.P./Alliance Global Partners (the “Agent”), relating to shares of our common stock, par value $0.001 per share |
|
| January 31, 2020 |
Form of Securities Purchase Agreement** Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January , 2020, and is between Cocrystal Pharma, Inc., a corporation incorporated under the laws of the state of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchase |
|
| January 31, 2020 |
Placement Agency Agreement, dated January 29, 2020 Exhibit 1.1 January 28, 2020 Cocrystal Pharma, Inc. 19805 N. Creek Parkway Bothell, WA 98011 Attention: Gary Wilcox Chief Executive Officer Dear Mr. Wilcox: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (“A.G.P.” or the “Placement Agent”) and Cocrystal Pharma, Inc., a company organized under the laws of the state of Delaware (th |
|
| January 31, 2020 |
A.G.P. The date of this prospectus supplement is January 29, 2020 Filed pursuant to Rule 424(b)(5) Registration No. 333-220632 PROSPECTUS SUPPLEMENT (To the Prospectus dated October 10, 2017) 3,492,063 Shares of Common Stock We are offering up to 3,492,063 shares of our common stock, par value $0.001 per share at a purchase price of $0.63 per share of common stock to institutional investors pursuant to this prospectus supplement and the accompanying prospectus a |
|
| January 31, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2020 Cocrystal Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38418 35-2528215 (State or other Jurisdiction of Incorporation) (Commission |
|
| January 29, 2020 |
Amendment No. 1 to the Amended and Restated Equity Distribution Agreement Cocrystal Pharma, Inc. 19805 N. Creek Parkway Bothell, WA 98011 January 29, 2020 A.G.P./Alliance Global Partners 590 Madison Avenue, 36th Floor New York, New York 10022 Ladies and Gentlemen: This letter agreement documents our understanding regarding amending that certain Amended and Restated Equity Distribution Agreement between Cocrystal Pharma, Inc. (the “Company”) and A.G.P./Alliance Global Pa |
